ClinicalTrials.gg
RecruitingNCT06116682Updated Oct 9, 2026

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

A Phase 2 interventional study of Amivantamab and Biospecimen Collection in Lung Non-Small Cell Carcinoma, sponsored by SWOG Cancer Research Network. Recruiting at 271 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by SWOG Cancer Research Network · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 9, 2026Site recruiting status changed26 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung — 4 open to participants now, 14 under way, 3 of them phase 3. amivantamab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
7th of 15
88 · median 80
Started
2024
with 4 others
Phase 2
6 of 15
4 open now
Primary completion
2028-05
later than 12 of 13 live
Registered
10th of 15
by date
Lead sponsor
1 of 15
SWOG Cancer Research Network

Among the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by planned enrollment, is one of 5 that started in 2024, is one of 6 in phase 2, reaches primary completion later than 12 of the 13 other live ones, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About amivantamab

amivantamab: first FDA approval 2021 (RYBREVANT), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing amivantamab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the objective response rate (ORR) (confirmed and unconfirmed, complete and partial) in participants with MET amplification-positive non-small cell lung cancer (NSCLC) treated with amivantamab-SC within each cohort.

SECONDARY OBJECTIVES:

I. To evaluate progression-free survival (PFS) within each cohort. II. To evaluate overall survival (OS) within each cohort. III. To evaluate the duration of response among responders within each cohort. IV. To evaluate the frequency and severity of toxicities within each cohort and combined across all study participants.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To collect, process, and bank cell-free deoxyribonucleic acid (cfDNA) prior to treatment on Cycle 1 Day 1, Cycle 3 Day 1, and at first progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor deoxyribonucleic acid (ctDNA).

II. To establish a tissue/blood repository from participants with refractory non-small cell lung cancer (NSCLC).

OUTLINE:

Patients receive amivantamab subcutaneously (SC) on days 1, 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computerized tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.

After completion of study treatment, patients are followed up for up to 3 years.

03

Conditions studied

  • Lung Non-Small Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Participants must have been assigned to S1900J by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900J is determined by the LUNGMAP protocol
  • Participants must have documentation of NSCLC with MET amplification determined by FMI tissue-based next generation sequencing (NGS) assay
  • Participants must have documented by CT or MRI. The CT from a combined positron emission tomography (PET)/CT may be used to document measurable disease ONLY if it is of diagnostic quality: otherwise, it may be used to document non-measurable disease only. Measurable disease must be assessed within 28 days prior to sub-study registration. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to sub-study registration. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to sub-study registration to be considered measurable
  • Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study registration
  • Participants with asymptomatic (brain metastases or ) must be clinically stable and asymptomatic for at least 14 days prior to sub-study registration

    • NOTE: Participants can be on a low-dose treatment (≤ 10 mg prednisone or equivalent) for at least 14 days prior to study treatment
  • Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, mutation, KRAS activating mutations, and BRAF V600E mutation
  • Participants must have progressed (in the opinion of the treating physician) following the most recent
  • Participants must have received at least one line of systemic treatment for Stage IV or recurrent NSCLC
  • Participants must have recovered (≤ Grade 1) from any side effects of prior therapy. The exception is if a side effect from a prior treatment is known to be permanent without expected further recovery or resolution (i.e., endocrinopathy from immunotherapy or cisplatin neurotoxicity)
  • Participants must not have been previously treated for any cancer with MET tyrosine kinase inhibitors (TKIs) such as tepotinib, capmatinib, and crizotinib
  • Participants must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or drug) within 21 days prior to sub-study registration
  • Participants must not have a prior treatment with or anti-PD-L1 antibody within 6 weeks of sub-study registration
  • Participants must not have received any radiation therapy within 14 days prior to sub-study registration
  • Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
  • Participants must not have had major surgery excluding placement of vascular access or tumor , or had significant traumatic injury within 28 days prior to sub-study registration, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study

    • NOTE: Participants with planned surgical procedures to be conducted under local anesthesia may participate
  • Participants must not have a prior or concurrent whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
  • ≥ 1.5 x 10\^3/uL (within 28 days prior to sub-study registration)
  • >= 10.0 g/dL (within 28 days prior to sub-study registration)
  • ≥ 75 x 10\^3/uL (within 28 days prior to sub-study registration)
  • Total ≤ 1.5 x institutional (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN (within 28 days prior to sub-study registration)
  • (AST) and alanine aminotransferase (ALT) ≤ 3 × institutional ULN. Participants with history of liver must have AST and ALT ≤ 5 x ULN (within 28 days prior to sub-study registration)
  • Participants must have a serum creatinine ≤ the institutional upper limit of normal (IULN) or calculated ≥ 45 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study registration. For creatinine clearance formula see the tools on the CRA Workbench
  • Participants' most recent Zubrod performance status must be 0-2 and be documented within 28 days prior to sub-study registration
  • Participants must have a completed medical history and physical exam within 28 days prior to sub-study registration
  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, participants must be class 2B or better
  • Participants with known (HIV)-infection must be on effective anti-retroviral therapy and have undetectable viral load test on the most recent test results obtained within 6 months prior to sub-study registration
  • Participants with evidence of chronic virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to sub-study registration
  • Participants with a history of virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to sub-study registration
  • Participants with known diabetes as determined by the treating investigator must show evidence of controlled disease within 14 days prior to sub-study registration
  • Participants of must have a negative serum pregnancy test within 7 days prior to sub-study registration
  • Participants must not have other clinically active infectious liver disease
  • Participants must not have hypertension within 28 days prior to sub-study registration as determined by the treating investigator
  • Participants must not have a history of pneumonitis that required drug therapy or an active symptomatic interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
  • Participants must not have ongoing or active infection or be diagnosed or suspected viral infection as determined by the treating investigator. NOTE: Participants that have an infection requiring antimicrobial therapy will be required to complete antibiotics 1 week prior to starting treatment
  • Participants must not have active bleeding diathesis as determined by the treating investigator
  • Participants must not have impaired oxygenation requiring continuous oxygen supplementation as determined by the treating investigator
  • Participants must not have psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements as determined by the treating investigator
  • Participants must not have any ophthalmologic condition that is unstable in the opinion of the treating investigator
  • Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
  • Participants must agree to have blood specimens submitted for circulating tumor DNA (ctDNA)
  • Participants must also be offered participation in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
  • Participants must be informed of the investigational nature of this study and must sign and give in accordance with institutional and federal guidelines

    • NOTE: Participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Treatment (amivantamab)

    Patients receive amivantamab SC on days 1, 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI and collection of blood samples throughout the trial.

    Biological: Amivantamab · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging

Interventions

  • BiologicalAmivantamab

    Given amivantamab-SC

    Also known as: Amivantamab-vmjw, Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372, CNTO-4424, JNJ 61186372, JNJ-611, JNJ-61186372, JNJ61186372, Rybrevant

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

06

What researchers measure

Primary outcomes

  1. Response rate for amivantamab-subcutaneous

    Response rates and associated confidence intervals will be calculated.

    Time frame: Up to 3 years

Secondary outcomes

  1. Overall survival

    Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to calculate confidence intervals for median times.

    Time frame: Up to 3 years

  2. Progression free survival

    Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to calculate confidence intervals for median times.

    Time frame: Up to 3 years

  3. Duration of response

    Will be estimated using the method of Kaplan-Meier. The Brookmeyer-Crowley method will be used to calculate confidence intervals for median times.

    Time frame: Up to 3 years

  4. Incidence of adverse events

    Toxicity will be evaluated among all participants enrolled on the study (combining the squamous and non-squamous cohorts). With 80 participants, any toxicity can be estimated to within 11% with 95% confidence. Any toxicity with at least 5% prevalence has at least a 98% chance of being observed.

    Time frame: Up to 28 days

07

Study locations

250 of 271 sites recruiting

Showing the first 100 of 271 sites. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2028, 42 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 42 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 3, 2023
StartActual
Nov 19, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
26 sites added, 3 sites removed. 20 sites changed recruiting status (10 now suspended, 8 now active, not recruiting, …)
Show 20 sites
  • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesSuspended→Recruiting
  • Eisenhower Medical Center · Rancho Mirage, United StatesRecruiting→Suspended
  • SSM Health Good Samaritan · Mount Vernon, United StatesSuspended→Recruiting
  • Henry Ford Cancer Institute-Downriver · Brownstown, United StatesRecruiting→Active, not recruiting
  • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesRecruiting→Active, not recruiting
  • Henry Ford Medical Center-Fairlane · Dearborn, United StatesRecruiting→Active, not recruiting
  • Henry Ford Hospital · Detroit, United StatesRecruiting→Active, not recruiting
  • Allegiance Health · Jackson, United StatesRecruiting→Active, not recruiting
  • Trinity Health Muskegon Hospital · Muskegon, United StatesRecruiting→Suspended
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesRecruiting→Suspended
  • Henry Ford Medical Center-Columbus · Novi, United StatesRecruiting→Active, not recruiting
  • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesRecruiting→Active, not recruiting
  • Henry Ford Wyandotte Hospital · Wyandotte, United StatesRecruiting→Active, not recruiting
  • OptumCare Cancer Care at Charleston · Las Vegas, United StatesRecruiting→Suspended
  • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesRecruiting→Suspended
  • Providence Newberg Medical Center · Newberg, United StatesRecruiting→Suspended
  • Providence Willamette Falls Medical Center · Oregon City, United StatesRecruiting→Suspended
  • Providence Portland Medical Center · Portland, United StatesRecruiting→Suspended
  • Providence Saint Vincent Medical Center · Portland, United StatesRecruiting→Suspended
  • Cancer Care Associates of York · York, United StatesRecruiting→Suspended
Show 26 added (26 United States)
  • Kaiser San Rafael-Gallinas · San Rafael, United States
  • Mayo Clinic in Florida · Jacksonville, United States
  • Emory University Hospital Midtown · Atlanta, United States
  • Emory University Hospital/Winship Cancer Institute · Atlanta, United States
  • Northwest Cancer Center - Crown Point · Crown Point, United States
  • Northwest Oncology LLC · Dyer, United States
  • Saint Mary Medical Center · Hobart, United States
  • Saint Catherine Hospital · Indianapolis, United States
  • The Community Hospital · Munster, United States
  • Women's Diagnostic Center - Munster · Munster, United States
  • Northwest Cancer Center - Valparaiso · Valparaiso, United States
  • Physicians' Clinic of Iowa PC · Cedar Rapids, United States
  • Lahey Clinic · Burlington, United States
  • Lahey Clinic Peabody · Peabody, United States
  • Mayo Clinic in Rochester · Rochester, United States
  • UPMC Hillman Cancer Center Erie · Erie, United States
  • UPMC Cancer Centers - Arnold Palmer Pavilion · Greensburg, United States
  • WellSpan Medical Oncology and Hematology · Hanover, United States
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus · Harrisburg, United States
  • IRMC Cancer Center · Indiana, United States
  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion · Mechanicsburg, United States
  • UPMC Hillman Cancer Center - Monroeville · Monroeville, United States
  • UPMC-Saint Margaret · Pittsburgh, United States
  • UPMC Hillman Cancer Center · Pittsburgh, United States
  • UPMC-Passavant Hospital · Pittsburgh, United States
  • UPMC Cancer Center-Washington · Washington, United States
Show 3 removed
  • Lahey Hospital and Medical Center · Burlington, United States
  • Lahey Medical Center-Peabody · Peabody, United States
  • BJC Outpatient Center at Sunset Hills · Sunset Hills, United States
Oct 9, 2026
Site contacts
Changed at 27 sites. See the sites
Show 27 sites
  • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
  • Eisenhower Medical Center · Rancho Mirage, United StatesContact removed •••3798Contact removed (no phone or email listed)
  • Bayhealth Hospital Kent Campus · Dover, United StatesContact person changed (no phone or email listed)
  • Bayhealth Hospital Sussex Campus · Milford, United StatesContact person changed (no phone or email listed)
  • Loyola University Medical Center · Maywood, United StatesContact person changed (no phone or email listed)
  • SSM Health Good Samaritan · Mount Vernon, United StatesContact added g•••@ssmhealth.com · •••1894Contact added (no phone or email listed)
  • Henry Ford Cancer Institute-Downriver · Brownstown, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
  • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
  • Henry Ford Medical Center-Fairlane · Dearborn, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
  • Henry Ford Hospital · Detroit, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
  • Allegiance Health · Jackson, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
  • Trinity Health Muskegon Hospital · Muskegon, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
  • Henry Ford Medical Center-Columbus · Novi, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
  • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
  • Henry Ford Wyandotte Hospital · Wyandotte, United StatesContact removed n•••@hfhs.orgContact removed (no phone or email listed)
  • OptumCare Cancer Care at Charleston · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
  • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
  • Providence Newberg Medical Center · Newberg, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  • Providence Willamette Falls Medical Center · Oregon City, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  • Providence Portland Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  • Geisinger Medical Center · Danville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
  • Geisinger Cancer Center Dickson City · Dickson City, United StatesContact h•••@geisinger.edu→c•••@geisinger.edu
  • Geisinger Medical Oncology-Lewisburg · Lewisburg, United StatesContact •••8555→•••9200Contact H•••@geisinger.edu→c•••@geisinger.edu
  • Community Medical Center · Scranton, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
  • Cancer Care Associates of York · York, United StatesContact removed •••9229Contact removed (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    26 sites added, 3 sites removed. 20 sites changed recruiting status (10 now suspended, 8 now active, not recruiting, …)
    Show 20 sites
    • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesSuspended→Recruiting
    • Eisenhower Medical Center · Rancho Mirage, United StatesRecruiting→Suspended
    • SSM Health Good Samaritan · Mount Vernon, United StatesSuspended→Recruiting
    • Henry Ford Cancer Institute-Downriver · Brownstown, United StatesRecruiting→Active, not recruiting
    • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesRecruiting→Active, not recruiting
    • Henry Ford Medical Center-Fairlane · Dearborn, United StatesRecruiting→Active, not recruiting
    • Henry Ford Hospital · Detroit, United StatesRecruiting→Active, not recruiting
    • Allegiance Health · Jackson, United StatesRecruiting→Active, not recruiting
    • Trinity Health Muskegon Hospital · Muskegon, United StatesRecruiting→Suspended
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesRecruiting→Suspended
    • Henry Ford Medical Center-Columbus · Novi, United StatesRecruiting→Active, not recruiting
    • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesRecruiting→Active, not recruiting
    • Henry Ford Wyandotte Hospital · Wyandotte, United StatesRecruiting→Active, not recruiting
    • OptumCare Cancer Care at Charleston · Las Vegas, United StatesRecruiting→Suspended
    • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesRecruiting→Suspended
    • Providence Newberg Medical Center · Newberg, United StatesRecruiting→Suspended
    • Providence Willamette Falls Medical Center · Oregon City, United StatesRecruiting→Suspended
    • Providence Portland Medical Center · Portland, United StatesRecruiting→Suspended
    • Providence Saint Vincent Medical Center · Portland, United StatesRecruiting→Suspended
    • Cancer Care Associates of York · York, United StatesRecruiting→Suspended
    Show 26 added (26 United States)
    • Kaiser San Rafael-Gallinas · San Rafael, United States
    • Mayo Clinic in Florida · Jacksonville, United States
    • Emory University Hospital Midtown · Atlanta, United States
    • Emory University Hospital/Winship Cancer Institute · Atlanta, United States
    • Northwest Cancer Center - Crown Point · Crown Point, United States
    • Northwest Oncology LLC · Dyer, United States
    • Saint Mary Medical Center · Hobart, United States
    • Saint Catherine Hospital · Indianapolis, United States
    • The Community Hospital · Munster, United States
    • Women's Diagnostic Center - Munster · Munster, United States
    • Northwest Cancer Center - Valparaiso · Valparaiso, United States
    • Physicians' Clinic of Iowa PC · Cedar Rapids, United States
    • Lahey Clinic · Burlington, United States
    • Lahey Clinic Peabody · Peabody, United States
    • Mayo Clinic in Rochester · Rochester, United States
    • UPMC Hillman Cancer Center Erie · Erie, United States
    • UPMC Cancer Centers - Arnold Palmer Pavilion · Greensburg, United States
    • WellSpan Medical Oncology and Hematology · Hanover, United States
    • UPMC Pinnacle Cancer Center/Community Osteopathic Campus · Harrisburg, United States
    • IRMC Cancer Center · Indiana, United States
    • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion · Mechanicsburg, United States
    • UPMC Hillman Cancer Center - Monroeville · Monroeville, United States
    • UPMC-Saint Margaret · Pittsburgh, United States
    • UPMC Hillman Cancer Center · Pittsburgh, United States
    • UPMC-Passavant Hospital · Pittsburgh, United States
    • UPMC Cancer Center-Washington · Washington, United States
    Show 3 removed
    • Lahey Hospital and Medical Center · Burlington, United States
    • Lahey Medical Center-Peabody · Peabody, United States
    • BJC Outpatient Center at Sunset Hills · Sunset Hills, United States
    Site contacts Changed at 27 sites. See the sites
    Show 27 sites
    • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Eisenhower Medical Center · Rancho Mirage, United StatesContact removed •••3798Contact removed (no phone or email listed)
    • Bayhealth Hospital Kent Campus · Dover, United StatesContact person changed (no phone or email listed)
    • Bayhealth Hospital Sussex Campus · Milford, United StatesContact person changed (no phone or email listed)
    • Loyola University Medical Center · Maywood, United StatesContact person changed (no phone or email listed)
    • SSM Health Good Samaritan · Mount Vernon, United StatesContact added g•••@ssmhealth.com · •••1894Contact added (no phone or email listed)
    • Henry Ford Cancer Institute-Downriver · Brownstown, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Henry Ford Medical Center-Fairlane · Dearborn, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Henry Ford Hospital · Detroit, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Allegiance Health · Jackson, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Trinity Health Muskegon Hospital · Muskegon, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
    • Henry Ford Medical Center-Columbus · Novi, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Henry Ford Wyandotte Hospital · Wyandotte, United StatesContact removed n•••@hfhs.orgContact removed (no phone or email listed)
    • OptumCare Cancer Care at Charleston · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
    • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
    • Providence Newberg Medical Center · Newberg, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Geisinger Medical Center · Danville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
    • Geisinger Cancer Center Dickson City · Dickson City, United StatesContact h•••@geisinger.edu→c•••@geisinger.edu
    • Geisinger Medical Oncology-Lewisburg · Lewisburg, United StatesContact •••8555→•••9200Contact H•••@geisinger.edu→c•••@geisinger.edu
    • Community Medical Center · Scranton, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
    • Cancer Care Associates of York · York, United StatesContact removed •••9229Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06116682
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Nov 19, 2024
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Shirish Gadgeel
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amivantamab

Start the discussion